Company intelligence / Profile preview

Aucta Pharmaceuticals, Inc.

Piscataway, New Jersey, United Statesauctapharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Aucta successfully launched its first branded product, Motpoly XR (lacosamide), in the epilepsy space in mid-February 2024. The FDA approved Motpoly XR for partial onset seizures in May 2023, and it received a new indication for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment) in June 2024[3][7].

Therapeutic areas: OphthalmologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecule drugsMolecular glue
Industry: Biotech

Drug pipeline

5 assets

AU4382A

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aucta Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aucta Pharmaceuticals, Inc..

Explore the full profile